Novavax stock fell 12.17 percent on October 16, 2026, 15.91 percent below its 52-week high

Published on 10/17/2026 at 19:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue fell 76.20 percent to USD 56.70 million in second quarter 2026. Novavax stock was USD 11.26 on October 16, 2026, down 12.17 percent on Nasdaq.

Price move and operating figures

Novavax stock fell 12.17 percent on October 16, 2026, on Nasdaq.
Second-quarter revenue fell 76.20 percent to USD 56.70 million in 2026.
Novavax stock was USD 11.26 at 4:00 p.m. ET on October 16, 2026, down 12.17 percent from the Nasdaq prior close.
Citigroup raised its target from USD 7.00 to USD 8.00 on October 15, 2026.

NVAX, US6700024010, Illustration mit AI erstellt.

Novavax stock fell 12.17 percent on Nasdaq on October 16, 2026, marking the clearest market signal in the latest completed session. The stock was last at USD 11.26 at 4:00 p.m. ET, down from USD 12.82 at the prior close.

Second-quarter revenue fell 76.20 percent

The operating backdrop remains central to the valuation. According to Simply Wall St on October 12, 2026, second-quarter 2026 revenue fell 76.20 percent year over year to USD 56.70 million, while net loss reached USD 53.40 million. The comparison was stark: revenue had been USD 239.24 million in the second quarter of 2025, and the company moved from a USD 0.62 adjusted earnings-per-share profit to a USD 0.32 adjusted loss per share.

The latest quarterly figures therefore provide a counterweight to the stock's earlier advance. They also give the October 16 decline a measurable operating reference rather than leaving the move as a standalone chart event.

The stock sits 15.91 percent below its high

Novavax's USD 6.20 to USD 13.39 52-week range places the latest USD 11.26 price 15.91 percent below the high and USD 5.06 above the low. Trading volume reached 9,869,003 shares against an average of 5,865,723 shares in the latest quoted session.

Valuation and November 5 date

Citigroup analyst Geoff Meacham raised the price target from USD 7.00 to USD 8.00 and kept a Sell rating on October 15, 2026, as Markets Insider reported. The target remains below the latest Nasdaq price. A next earnings date of November 5, 2026, was listed by TradingView.

Comparison with peers

NVAX: minus 12.17 percent, price-to-earnings ratio minus 7.41, market capitalization USD 1.9 billion.

Moderna (Nasdaq, USD): minus 7.82 percent, price-to-earnings ratio minus 27.32, market capitalization USD 87.0 billion.

Pfizer (NYSE, USD): plus 0.48 percent, price-to-earnings ratio 39.09, market capitalization USD 168.6 billion.

What the October 16 move changes

Novavax's market value remains far below those larger vaccine companies, while its latest quarterly revenue is also materially smaller. The next scheduled reporting date gives the market a defined point at which the company can update the figures and its partnership-led commercial picture.

On Nasdaq, Novavax was last at USD 11.26 on October 16, 2026 at 4:00 p.m. ET, down 12.17 percent from the prior close.